The association was much stronger for those with triple-negative cancer (OR = 6.70 (95% OR 2.18–20.56, p = 0.001)) than for those with HER2-positive cancer (OR = 1.65 (95% OR 0.70–3.88, p = 0.25)). Here, ERBB2 is linked to cancer.